The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers

Arthritis and Rheumatism

Volumn 65, Issue 1, 2013, Pages 88-97

  Fabris, Martina ^a   Quartuccio, Luca ^a   Vital, Ed ^b   Pontarini, Elena ^a   Salvin, Sara ^a   Fabro, Cinzia ^a   Zabotti, Alen ^a   Benucci, Maurizio ^c   Manfredi, Mariangela ^c   Ravagnani, Viviana ^d   Biasi, Domenico ^d   Atzeni, Fabiola ^e   Sarzi Puttini, Piercarlo ^e   Morassi, Pia ^f   Fischetti, Fabio ^f   Bazzicchi, Laura ^g   Saracco, Marta ^h   Pellerito, Raffaele ^h   Cimmino, Marco ⁱ   Carraro, Valeria ^j   Semeraro, Angelo ^k   Schiavon, Franco ^j   Caporali, Roberto ^l   Bortolotti, Roberto ^m   Govoni, Marcello ⁿ   Fogolari, Federico ^a   Tonutti, Elio ^a   Bombardieri, Stefano ^g   Emery, Paul ^b   De Vita, Salvatore ^a   more..

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Ospedale San Giovanni di Dio   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h MAURIZIANO HOSPITAL   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j UNIVERSITY OF PADOVA   (Italy)

^k Ospedale Valle d'Itria Martina Franca   (Italy)

^l UNIVERSITY OF PAVIA   (Italy)

^m Santa Chiara Hospital Trent   (Italy)

ⁿ UNIVERSITY HOSPITAL OF FERRARA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; EXPECTATION MAXIMIZATION ALGORITHM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; BLOOD SEDIMENTATION; COHORT STUDIES; DRUG RESISTANCE; ENGLAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAPLOTYPES; HUMANS; ITALY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84871797558     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37707     Document Type: Article

References (44)

1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
2. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1557-9.
3. Tak PP, Cohen S, Emery P, Saadeh CK, De Vita S, Donohue JP, et al. Baseline autoantibody status (RF, anti-CCP) and clinical response following the first treatment course with rituximab [abstract]. Arthritis Rheum 2006; 54 Suppl: S368-9.
4. Van Vollenhoven RF, Chatzidionysiou K, Gabay C, Hetland ML, Tarp U, Gomez-Reino JJ, et al. Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the Collaborative European Registries for Rituximab in Rheumatoid Arthritis (CERERRA). Ann Rheum Dis 2009; 68 Suppl III: iii579.
5. Pyrpasopoulou A, Douma S, Triantafyllou A, Simoulidou E, Samara M, Parapanisiou E, et al. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther 2010; 14: 43-8.
6. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
7. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G,. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029-33.
8. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
9. De Vita S, Quartuccio L,. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 2006; 5: 443-8.
10. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al, on behalf of the physicians of the Swiss Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56: 1417-23.
11. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP,. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-25.
12. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP,. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 772-8.
13. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M,. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009; 11: R123.
14. Treml JF, Hao Y, Stadanlick JE, Cancro MP,. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009; 53: 1-16.
15. Mackay F, Sierro F, Grey ST, Gordon TP,. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005; 8: 243-65.
16. Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T, Kuroki H, et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36: 365-72.
17. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K,. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3: 424-9.
18. Gottenberg JE, Sellam J, Ittah M, Lavie F, Proust A, Zouali H, et al. No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome. Arthritis Res Ther 2006; 8: R30.
19. Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007; 136: 309-14.
20. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011-6.
21. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC,. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723-32.
22. Fabris M, Quartuccio L, Saracco M, Pellerito R, Atzeni F, Sarzi-Puttini P, et al. BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Ann Rheum Dis 2009; 68 Suppl III: iii75.
23. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M,. Polymorphism in the 5′ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjögren's syndrome. Rheumatology (Oxford) 2008; 47: 1311-6.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
26. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
27. Emery P, Dorner T,. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011; 70: 2063-70.
28. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 2012; 71: 351-7.
29. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45.
30. Bugatti S, Manzo A, Bombardieri M, Vitolo B, Humby F, Kelly S, et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 2011; 13: 440-8.
31. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Huizinga TW, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody- negative rheumatoid arthritis. Arthritis Rheum 2005; 52: 3058-62.
32. Lee HS, Lee AT, Criswell LA, Seldin MF, Amos CI, Carulli JP, et al. Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol Med 2008; 14: 293-300.
33. Li H, Zou Q, Xie Z, Liu Y, Zhong B, Yang S, et al. A haplotype in STAT4 gene associated with rheumatoid arthritis in Caucasians is not associated in the Han Chinese population, but with the presence of rheumatoid factor. Rheumatology (Oxford) 2009; 48: 1363-8.
34. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
35. Van der Woude D, Lie BA, Lundstrom E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, et al. Protection against anti- citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 2010; 62: 1236-45.
36. Skinningsrud B, Lie BA, Husebye ES, Kvien TK, Forre O, Flato B, et al. A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1471-4.
37. Ates A, Karaaslan Y, Karatayli E, Ertugrul E, Aksaray S, Turkyilmaz A, et al. Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients. Tissue Antigens 2011; 78: 56-9.
38. Montes A, Dieguez-Gonzalez R, Perez-Pampin E, Calaza M, Mera-Varela A, Gomez-Reino JJ, et al. Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis. Arthritis Rheum 2011; 63: 654-61.
39. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174: 864-70.
40. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-92.
41. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-26.
42. Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008; 2: 38-43.
43. Youinou P, Pers JO,. The late news on BAFF in autoimmune diseases. Autoimmun Rev 2010; 9: 804-6.
44. Le Pottier L, Bendaoud B, Renaudineau Y, Youinou P, Pers JO, Daridon C,. New ELISA for B cell-activating factor. Clin Chem 2009; 55: 1843-51.